<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alitretinoin (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alitretinoin (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alitretinoin (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="89747" href="/d/html/89747.html" rel="external">see "Alitretinoin (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20520575"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Panretin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F20520577"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Retinoic Acid Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F20520606"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e277760f-af35-4e5a-8166-c0fa9448be33">Kaposi sarcoma, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kaposi sarcoma, cutaneous:</b>
<b>Topical:</b> Initial: Apply gel twice daily to cutaneous lesions; may gradually increase application frequency to 3 or 4 times daily based on lesion tolerance. Continue as long as deriving clinical benefit; response may be observed within 2 weeks of initiation; however, most patients require a longer period, and further benefit may be attained with a longer application period (&gt;14 weeks) in some patients. In clinical trials, therapy lasted up to 96 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990116"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, systemic absorption is not extensive making the need for a dose adjustment appear unlikely.</p></div>
<div class="block doha drugH1Div" id="F50987432"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, systemic absorption is not extensive making the need for a dose adjustment appear unlikely.</p></div>
<div class="block dot drugH1Div" id="F20520609"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Alitretinoin (Topical</b>
<b>) Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Alitretinoin (topical) dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Walmsley 1999.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Bodsworth 2001.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">
<b>
<b>Dermal irritation</b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">May reduce the frequency of administration if application site toxicity occurs.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤ Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Reduce dosing frequency or withhold alitretinoin (topical) for up to 2 weeks; may resume when irritation improves to ≤ grade 1<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">reduce dosing frequency to once daily.<sup>b</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold alitretinoin (topical) for up to 2 weeks; may resume at a reduced application frequency (less than once daily) when irritation improves to ≤ grade 1. Continue reduced application frequency for 2 weeks prior to increasing.<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">If grade 4 dermal irritation occurs at reduced application frequency (less than once daily), discontinue alitretinoin (topical).<sup>a</sup></p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58737542"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F20520589"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Pain (≤34%), paresthesia (3% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (25% to 77%), pruritus (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Edema (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Exfoliative dermatitis (3% to 9%), dermatological disease (≤8%)</p></div>
<div class="block coi drugH1Div" id="F20520586"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to alitretinoin, other retinoids, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F20520587"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermal irritation: Application site irritation and pain have been reported, including grade 3 dermal irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Alitretinoin may be photosensitizing (based on experience with other retinoids); minimize sun or other UV exposure of treated areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Products containing DEET: Do not use concurrently with topical products containing DEET (eg, insect repellant); an increase in DEET toxicity has been observed.</p></div>
<div class="block foc drugH1Div" id="F20520617"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panretin: 0.1% (60 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panretin: 0.1% (60 g) [contains alcohol, usp]</p></div>
<div class="block geq drugH1Div" id="F20520576"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F20520619"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Panretin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $115.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F20520610"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> Apply sufficient gel to cover lesion(s) with a generous coating; allow gel to dry for 3 to 5 minutes after application before covering with clothing. Do not cover alitretinoin application site with occlusive dressings. Avoid applying gel to healthy skin surrounding lesions; do not apply on or near mucosal surfaces. Advise patients to avoid sun or UV light exposure to the treated area. Patients should wait 20 minutes after showering or bathing before applying alitretinoin (topical) and avoid showering, bathing, or swimming for at least 3 hours following application.</p></div>
<div class="block hazard drugH1Div" id="F49104426"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F20520581"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kaposi sarcoma, cutaneous:</b> Topical treatment of cutaneous lesions in AIDS-related Kaposi sarcoma (KS).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Alitretinoin is not indicated when systemic therapy for KS is necessary (eg, &gt;10 new lesions in previous month, symptomatic visceral involvement, symptomatic pulmonary KS, symptomatic lymphedema). There is no experience in using alitretinoin (topical) in combination with systemic treatment for KS.</p></div>
<div class="block mst drugH1Div" id="F20520569"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Alitretinoin (topical) may be confused with tretinoin (topical).</p>
<p style="text-indent:-2em;margin-left:4em;">Panretin may be confused with pancreatin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F20520593"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F20520594"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095553"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant should avoid becoming pregnant during treatment with topical alitretinoin.</p></div>
<div class="block pri drugH1Div" id="F20520583"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">In utero exposure to alitretinoin (topical) may cause fetal harm if significant absorption occurs.</p></div>
<div class="block brc drugH1Div" id="F20520585"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if alitretinoin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during alitretinoin (topical) treatment.</p></div>
<div class="block pha drugH1Div" id="F20520600"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates intracellular retinoid receptors (RAR and RXR subtypes); this results in altered expression of the genes controlling cellular differentiation and proliferation in normal and neoplastic cells, inhibiting the growth of Kaposi sarcoma</p></div>
<div class="block phk drugH1Div" id="F20520602"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Not extensive</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26530101"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Panretin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11705307">
<a name="11705307"></a>Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. <i>Am J Clin Dermatol</i>. 2001;2(2):77-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alitretinoin-topical-drug-information/abstract-text/11705307/pubmed" id="11705307" target="_blank">11705307</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Panretin (alitretinoin) [prescribing information]. Concordia Pharmaceuticals; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770343">
<a name="10770343"></a>Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. <i>J Acquir Immune Defic Syndr</i>. 1999;22(3):235-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alitretinoin-topical-drug-information/abstract-text/10770343/pubmed" id="10770343" target="_blank">10770343</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 89684 Version 113.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
